<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Physiol</journal-id><journal-id journal-id-type="iso-abbrev">Front Physiol</journal-id><journal-id journal-id-type="publisher-id">Front. Physiol.</journal-id><journal-title-group><journal-title>Frontiers in Physiology</journal-title></journal-title-group><issn pub-type="epub">1664-042X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4170140</article-id><article-id pub-id-type="doi">10.3389/fphys.2014.00353</article-id><article-categories><subj-group subj-group-type="heading"><subject>Physiology</subject><subj-group><subject>Original Research Article</subject></subj-group></subj-group></article-categories><title-group><article-title>Remodeling of the heart in hypertrophy in animal models with myosin essential light chain mutations</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kazmierczak</surname><given-names>Katarzyna</given-names></name><xref ref-type="author-notes" rid="fn001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://community.frontiersin.org/people/u/183394"/></contrib><contrib contrib-type="author"><name><surname>Yuan</surname><given-names>Chen-Ching</given-names></name><uri xlink:type="simple" xlink:href="http://community.frontiersin.org/people/u/183395"/></contrib><contrib contrib-type="author"><name><surname>Liang</surname><given-names>Jingsheng</given-names></name></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Wenrui</given-names></name><uri xlink:type="simple" xlink:href="http://community.frontiersin.org/people/u/183438"/></contrib><contrib contrib-type="author"><name><surname>Rojas</surname><given-names>Ana I.</given-names></name><uri xlink:type="simple" xlink:href="http://community.frontiersin.org/people/u/182967"/></contrib><contrib contrib-type="author"><name><surname>Szczesna-Cordary</surname><given-names>Danuta</given-names></name><xref ref-type="author-notes" rid="fn001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://community.frontiersin.org/people/u/168041"/></contrib></contrib-group><aff><institution>Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine</institution><country>Miami, FL, USA</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Julien Ochala, King's College London, UK</p></fn><fn fn-type="edited-by"><p>Reviewed by: Ingo Morano, Max-Delbr&#252;xk-Center for Molecular Medicine, Germany; Yin-Biao Sun, King's College London, UK</p></fn><corresp id="fn001">*Correspondence: Katarzyna Kazmierczak and Danuta Szczesna-Cordary, University of Miami Miller School of Medicine, 1600 NW 10th Ave, Miami, FL 33136, USA e-mail: <email xlink:type="simple">kkazmierczak@med.miami.edu</email>; <email xlink:type="simple">dszczesna@med.miami.edu</email></corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Striated Muscle Physiology, a section of the journal Frontiers in Physiology.</p></fn></author-notes><pub-date pub-type="epub"><day>22</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>5</volume><elocation-id>353</elocation-id><history><date date-type="received"><day>19</day><month>6</month><year>2014</year></date><date date-type="accepted"><day>29</day><month>8</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#169; 2014 Kazmierczak, Yuan, Liang, Huang, Rojas and Szczesna-Cordary.</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Cardiac hypertrophy represents one of the most important cardiovascular problems yet the mechanisms responsible for hypertrophic remodeling of the heart are poorly understood. In this report we aimed to explore the molecular pathways leading to two different phenotypes of cardiac hypertrophy in transgenic mice carrying mutations in the human ventricular myosin essential light chain (ELC). Mutation-induced alterations in the heart structure and function were studied in two transgenic (Tg) mouse models carrying the A57G (alanine to glycine) substitution or lacking the N-terminal 43 amino acid residues (&#916;43) from the ELC sequence. The first model represents an HCM disease as the A57G mutation was shown to cause malignant HCM outcomes in humans. The second mouse model is lacking the region of the ELC that was shown to be important for a direct interaction between the ELC and actin during muscle contraction. Our earlier studies demonstrated that &gt;7 month old Tg-&#916;43 mice developed substantial cardiac hypertrophy with no signs of histopathology or fibrosis. Tg mice did not show abnormal cardiac function compared to Tg-WT expressing the full length human ventricular ELC. Previously reported pathological morphology in Tg-A57G mice included extensive disorganization of myocytes and interstitial fibrosis with no abnormal increase in heart mass observed in &gt;6 month-old animals. In this report we show that strenuous exercise can trigger hypertrophy and pathologic cardiac remodeling in Tg-A57G mice as early as 3 months of age. In contrast, no exercise-induced changes were noted for Tg-&#916;43 hearts and the mice maintained a non-pathological cardiac phenotype. Based on our results, we suggest that exercise-elicited heart remodeling in Tg-A57G mice follows the pathological pathway leading to HCM, while it induces no abnormal response in Tg-&#916;43 mice.</p></abstract><kwd-group><kwd>hypertrophic cardiomyopathy (HCM)</kwd><kwd>transgenic mice</kwd><kwd>myosin essential light chain</kwd><kwd>mutation</kwd><kwd>cardiac remodeling</kwd><kwd>histopathology</kwd></kwd-group><counts><fig-count count="9"/><table-count count="2"/><equation-count count="0"/><ref-count count="68"/><page-count count="12"/><word-count count="8867"/></counts></article-meta></front><body><sec sec-type="introduction" id="s1"><title>Introduction</title><p>In response to various types of stimuli (genetic, mechanical, hemodynamic, hormonal, physiological, environmental factors or their combination), the heart has the ability to adapt to increased workloads through the hypertrophy of muscle cells (Hunter and Chien, <xref rid="B29" ref-type="bibr">1999</xref>; Lorell and Carabello, <xref rid="B39" ref-type="bibr">2000</xref>). The hypertrophic response is considered physiological if the heart fully adapts to the new loading condition, reaching a new steady state. This type of hypertrophy is characterized by a normal organization of cardiac structure (normal cardiac morphology), normal or enhanced cardiac function and a relatively normal pattern of gene expression (Bernardo et al., <xref rid="B8" ref-type="bibr">2010</xref>). Hypertrophy can also be developed as a response to physiological stimuli such as chronic exercise. On the other hand, pathological hypertrophy is associated with an altered pattern of gene expression, presence of myofibrillar disarray, fibrosis, and contractile dysfunction and thus can lead to heart failure and sudden cardiac death (SCD) (Ho, <xref rid="B25" ref-type="bibr">2010</xref>; Ho et al., <xref rid="B26" ref-type="bibr">2010</xref>; Abel and Doenst, <xref rid="B1" ref-type="bibr">2011</xref>). Most commonly hypertrophic cardiomyopathy (HCM) occurs in response to genetic mutations in all major sarcomeric proteins, including the myosin essential light chain (ELC) encoded by the <italic>MYL3</italic> gene (Alcalai et al., <xref rid="B2" ref-type="bibr">2008</xref>).</p><p>There are number of studies demonstrating that physiological and pathological cardiac hypertrophy may be associated with distinct structural and functional as well as metabolic features (Abel and Doenst, <xref rid="B1" ref-type="bibr">2011</xref>; Weeks and McMullen, <xref rid="B64" ref-type="bibr">2011</xref>). It has also been shown that both physiologic and pathologic cardiac hypertrophy may display distinct biochemical and molecular signaling pathways (Iemitsu et al., <xref rid="B30" ref-type="bibr">2001</xref>; Heineke and Molkentin, <xref rid="B20" ref-type="bibr">2006</xref>; Bernardo et al., <xref rid="B8" ref-type="bibr">2010</xref>). Pathological cardiac hypertrophy is manifested by alterations in cardiac contractile proteins [&#945;-skeletal actin and the &#945;- to &#946;- myosin heavy chain (MHC) switch], increased expression of fetal genes such as atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP). The down- or up-regulation of calcium handling proteins such as the cardiac sarcoplasmic reticulum Ca<sup>2+</sup>-ATPase pump, SERCA2a can also be observed. Physiological cardiac hypertrophy may be associated with increased levels of peptide growth factors such as insulin-like growth factor-IGF 1 and epidermal growth factor and is often coupled to phosphatidylinositol 3-kinase (PI3K)/Akt pathway. It is known that many mutations in sarcomeric proteins cause cardiomyopathy and may ultimately initiate the hypertrophic gene remodeling program. Studies utilizing transgenic mouse models of hypertrophy are great tools for understanding the molecular pathways responsible for different forms of cardiac remodeling <italic>in vivo</italic>. Presented in this article study focuses on one particular sarcomeric protein, the essential light chain of myosin that is located in the neck region of the myosin cross-bridge (Rayment et al., <xref rid="B49" ref-type="bibr">1993</xref>), and was shown to be important for myosin contractile function in health and in heart disease (Sawicki et al., <xref rid="B52" ref-type="bibr">2005</xref>; Kazmierczak et al., <xref rid="B34" ref-type="bibr">2009</xref>, <xref rid="B33" ref-type="bibr">2013</xref>; Muthu et al., <xref rid="B46" ref-type="bibr">2011</xref>; Cadete et al., <xref rid="B10" ref-type="bibr">2012</xref>). Cardiac ventricular muscle exclusively expresses the long ELC isoform, containing the N-terminal extension, which was found to be important for the myosin-actin interaction during contraction and is expected to regulate heart performance (Winstanley et al., <xref rid="B65" ref-type="bibr">1977</xref>; Sutoh, <xref rid="B54" ref-type="bibr">1982</xref>; Henry et al., <xref rid="B21" ref-type="bibr">1985</xref>; Trayer et al., <xref rid="B58" ref-type="bibr">1987</xref>; Milligan et al., <xref rid="B42" ref-type="bibr">1990</xref>; Morano et al., <xref rid="B44" ref-type="bibr">1995</xref>; Timson et al., <xref rid="B57" ref-type="bibr">1998</xref>; Morano, <xref rid="B43" ref-type="bibr">1999</xref>; Timson, <xref rid="B56" ref-type="bibr">2003</xref>). The structural modeling study by Morano (Aydt et al., <xref rid="B5" ref-type="bibr">2007</xref>) depicts the N-terminus of the long myosin ELC as a rod-like 91 &#197;-long extension that can function as a bridge between the ELC core of the myosin head and the binding site of the ELC on the actin filament.</p><p>In this report we have studied cardiac remodeling in two forms of cardiac hypertrophy (pathological and non-pathological) related to the ventricular myosin ELC using transgenic mouse models carrying mutations in the human ventricular myosin ELC, Tg-A57G, and Tg-&#916;43. The A57G (Alanine replaced by Glycine) variant of ELC was found in two unrelated Korean families and one Japanese patient diagnosed with HCM (review in Hernandez et al., <xref rid="B22" ref-type="bibr">2007</xref>). The phenotype associated with this mutation was manifested as a classic asymmetric septal hypertrophy and SCD (Lee et al., <xref rid="B37" ref-type="bibr">2001</xref>). In the Tg-&#916;43 mouse model, the endogenous mouse ventricular ELC is partially replaced with the 43-amino-acid N-terminal truncated human ventricular ELC protein. We previously reported that Tg-&#916;43 mice hypertrophied with age (&gt;7 month-old), but the ventricles did not show any pathologic morphology. In support of the non-pathologic hypertrophy phenotype, an MRI (magnetic resonance imaging) assessment of Tg-&#916;43 hearts demonstrated normal cardiac function compared to age matched controls (Kazmierczak et al., <xref rid="B34" ref-type="bibr">2009</xref>).</p><p>Despite intensive research in many laboratories, questions about critical molecular mechanisms responsible for the transition from hypertrophy to heart failure still remain unanswered. Presented here transgenic mouse models carrying either the A57G mutation or the &#916;43 truncation in ELC protein, generated in our laboratory (Kazmierczak et al., <xref rid="B34" ref-type="bibr">2009</xref>, <xref rid="B33" ref-type="bibr">2013</xref>; Muthu et al., <xref rid="B46" ref-type="bibr">2011</xref>) represent different types of hypertrophy and therefore are valuable tools in understanding the pathological vs. non-pathological remodeling of the heart. We have examined the effects of both A57G and &#916;43 mutations on heart remodeling before and after strenuous exercise and characterized the functional effects of these mutations in mice subjected to strenuous exercise by swimming. The observed effects were compared to those seen in Tg-WT (wild-type) mice expressing the full length non-mutated human ventricular ELC. We show that remodeling of the heart in Tg-A57G mice follows the pathological pathway leading to HCM, while cardiac phenotype observed in Tg-&#916;43 mice is of non-pathological nature.</p></sec><sec sec-type="materials|methods"><title>Material and methods</title><sec><title>Transgenic mice</title><p>All animal studies were conducted in accordance with institutional guidelines and the protocol was reviewed and approved by the Animal Care and Use Committee at the University of Miami Miller School of Medicine (UMMSM). UMMSM has an Animal Welfare Assurance (A-3224-01, effective July 11, 2007) on file with the Office of Laboratory Animal Welfare (OLAW), National Institutes of Health. The generation and characterization of transgenic (Tg) mice used in this study and Tg protein expression profiles have been described earlier (Kazmierczak et al., <xref rid="B34" ref-type="bibr">2009</xref>, <xref rid="B33" ref-type="bibr">2013</xref>; Muthu et al., <xref rid="B46" ref-type="bibr">2011</xref>). Previously produced Tg-WT lines, L1, L3, and L4 expressing 88, 30, and 77% of WT-ELC (UniProtKB: P08590) and Tg-A57G lines, L1, L2, and L5 expressing 80, 55, and 75% of A57G-mutant, respectively were used in this study. As for Tg-&#916;43, two lines were used for this study, one previously generated expressing 40% of &#916;43 protein (L9), and the second line expressing 55% transgene which was generated by cross breeding of existing mice (L8 &#215; L8) in order to increase transgenic protein expression (Kazmierczak et al., <xref rid="B34" ref-type="bibr">2009</xref>). The percent of protein expression indicates the amount of replacement of the endogenous mouse cardiac ELC by human ventricular WT (UniProtKB: P08590) or its two mutants. In all experiments Tg-A57G and Tg-&#916;43 mice were gender and age matched with Tg-WT controls (Kazmierczak et al., <xref rid="B34" ref-type="bibr">2009</xref>; Muthu et al., <xref rid="B46" ref-type="bibr">2011</xref>; Kazmierczak et al., <xref rid="B33" ref-type="bibr">2013</xref>).</p><p>Chronic 4 week-long training by swimming of Tg-WT, Tg-A57G, and Tg-&#916;43 mice was performed in water at 30&#8211;32&#176;C (to avoid thermal stress). Initial swim time was set as 10 min, thereafter gradually increasing until 90 min sessions were reached. The 90-min training schedule was continued twice a day (separated by 4&#8211;5 h), 7 days a week, for 4 weeks. This protocol was demonstrated to be highly effective in promoting physiological hypertrophy in mice (Evangelista et al., <xref rid="B15" ref-type="bibr">2003</xref>; Galindo et al., <xref rid="B17" ref-type="bibr">2009</xref>).</p></sec><sec><title>Histological evaluation of the hearts from transgenic ELC mice</title><p>After euthanasia, the hearts from 3 to 5-month-old Tg-&#916;43, Tg-A57G, and Tg-WT mice were excised, weighed and immersed in 10% buffered formalin. Slides of whole mouse hearts were prepared at the Histology Laboratory (University of Miami Miller School of Medicine, Miami FL). The paraffin-embedded longitudinal sections of left ventricles (LV) of H&amp;E (hematoxylin and eosin) and Masson's trichrome stained hearts were examined for overall morphology and fibrosis using a Dialux 20 microscope, 40&#215;/0.65 NA (numerical aperture) Leitz Wetzlar objective and an AxioCam HRc (Zeiss) as described previously (Kazmierczak et al., <xref rid="B34" ref-type="bibr">2009</xref>, <xref rid="B33" ref-type="bibr">2013</xref>; Muthu et al., <xref rid="B46" ref-type="bibr">2011</xref>).</p></sec><sec><title>Skinned papillary muscle strips from transgenic mice</title><p>The papillary muscles of the left ventricles from 3 to 5 months old Tg-A57G L1 mice, Tg-&#916;43 (L9 and inbred cross of L8) and Tg-WT (L1, L3, and L4) mice were isolated, dissected into small muscle bundles and chemically skinned in 50% glycerol and 50% pCa 8 solution (10<sup>&#8722;8</sup> M [Ca<sup>2+</sup>], 1 mM free [Mg<sup>2+</sup>] (total MgPr (propionate) = 3.88 mM), 7 mM EGTA, 2.5 mM [Mg-ATP<sup>2&#8722;</sup>], 20 mM Mops, pH 7.0, 15 mM creatine phosphate and 15 units/ml of phosphocreatine kinase, ionic strength = 150 mM adjusted with KPr) containing 1% Triton X-100 for 24 h at 4&#176;C. Then the bundles were transferred to the same solution without Triton X-100 and stored at &#8722;20&#176;C for 4&#8211;6 days (Kazmierczak et al., <xref rid="B32" ref-type="bibr">2012</xref>).</p></sec><sec><title>Steady-state force measurements</title><p>Small muscle strips ~1.4 mm in length and 100 &#956;m in diameter were isolated from a batch of glycerinated skinned mouse papillary muscle bundles and attached by tweezer clips to the force transducer of the Guth Muscle Research System (Heidelberg, Germany). They were placed in a 1 ml cuvette and skinned in 1% Triton X-100 dissolved in pCa 8 buffer for 30 min, as described in Kazmierczak et al. (<xref rid="B32" ref-type="bibr">2012</xref>). Then they were rinsed in pCa 8 and their length adjusted to remove the slack. This procedure results in sarcomere length (SL) ~2.1 &#956;m as judged by the first order optical diffraction pattern as described in Muthu et al. (<xref rid="B46" ref-type="bibr">2011</xref>); Wang et al. (<xref rid="B62" ref-type="bibr">2013a</xref>,<xref rid="B63" ref-type="bibr">b</xref>); Huang et al. (<xref rid="B28" ref-type="bibr">2014</xref>). Muscle strips were then tested for steady state force development in pCa 4 solution (composition is the same as pCa 8 buffer except the [Ca<sup>2+</sup>] = 10<sup>&#8722;4</sup> M). All experiments were carried out at 21&#176;C. Maximal steady state tension measured in pCa 4 solution was expressed in Newtons per cross section of the muscle strip (kN/m<sup>2</sup>). The measurement of diameter was taken at ~3 points along the muscle strip length with an SZ6045 Olympus microscope (zoom ratio of 6.3:1, up to 189x maximum magnification) and averaged (Muthu et al., <xref rid="B45" ref-type="bibr">2012</xref>).</p></sec><sec><title>The Ca<sup>2+</sup> dependence of force development</title><p>After the initial steady state force was determined, muscle strips were relaxed in pCa 8 buffer and then exposed to solutions of increasing Ca<sup>2+</sup> concentrations from pCa 8 to 4 (Dweck et al., <xref rid="B14" ref-type="bibr">2005</xref>). Steady-state force was measured in each &#8220;pCa&#8221; solution followed by relaxation in pCa 8 solution. Data were analyzed using the Hill equation (Hill et al., <xref rid="B24" ref-type="bibr">1980</xref>) where &#8220;[Ca<sup>2+</sup>]<sub>50</sub> or pCa<sub>50</sub>&#8221; is the free Ca<sup>2+</sup> concentration which produces 50% maximum force, and &#8220;n<sub>H</sub>&#8221; is the Hill coefficient.</p></sec><sec><title>Assessment of myosin content in sedentary and exercised animals</title><p>Mouse cardiac myofibrils were prepared according to the method described previously (Kazmierczak et al., <xref rid="B33" ref-type="bibr">2013</xref>). Briefly, after euthanasia, the hearts from 3 to 5 months old transgenic mice were isolated and frozen in liquid nitrogen and stored at &#8722;80&#176;C until processed. For the preparation of myofibrils the tissue was thawed in the CMF (cardiac myofibril) buffer consisting 5 mM NaH<sub>2</sub>PO<sub>4</sub>, 5 mM Na<sub>2</sub>HPO<sub>4</sub>(pH 7.0), 0.1 mM NaCl, 5 mM MgCl<sub>2</sub>, 0.5 mM EGTA, 5 mM ATP, 5 nM microcystin, 0.1% Triton X-100, 20 mM NaF (phosphatase inhibitor), 5 mM DTT and 1 &#956;l/ml protease inhibitor cocktail (Sigma-Aldrich Corp., St. Louis, MO, USA). The tissue was then homogenized in a Mixer-Mill MM301 (Retsch) until homogenous. The homogenate was centrifuged for 4 min at 8000 g and the supernatant was discarded. After centrifugation, the pellets were left on ice for 4 min. This step was repeated three times until the pellet turned white. The pellets were then resuspended in the CMF buffer and the myofibrils were subsequently dissolved in Laemmli sample buffer and loaded on 15% SDS-PAGE. The thick and thin filament proteins were detected by Coomassie brilliant blue staining. Band intensities were measured using Image J software and ratios of total myosin regulatory light chain (RLC<sub>tot</sub>) to tropomyosin (RLC<sub>tot.</sub>/Tm) and RLC<sub>tot.</sub>/TnI (troponin I) were determined.</p></sec><sec><title>Myofilament protein phosphorylation in sedentary and exercised mice</title><p>Mouse cardiac myofibrils were used to determine sarcomeric protein phosphorylation. After separation of the samples on 15% SDS-PAGE Pro-Q Diamond phosphoprotein gel stain reagent (Invitrogen) was used (as described in the manufacturer's manual) to assess phosphorylation of troponin (TnT, TnI) and myosin RLC. The total protein was further detected in the same gel using the Coomassie brilliant blue staining. Myofilament protein phosphorylation ratio (ProQ) was calculated relative to the corresponding Coomassie brilliant blue staining (ProQ/Coomassie) using Image J software.</p></sec><sec><title>Assessment of gene expression changes in the hearts of Tg-A57G and Tg-&#916;43 mice</title><p>Total RNA was isolated from ventricles of sedentary and exercised Tg-WT, Tg-A57G, and Tg-&#916;43 mice and converted to double stranded cDNAs using Random Primers and a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) as described earlier (Kazmierczak et al., <xref rid="B34" ref-type="bibr">2009</xref>). Quantitative PCR was conducted using SYBR Green I chemistry with gene-specific Quantitect Primer Sets (Qiagen) for murine: ANP (atrial natriuretic factor: NM_008725), BNP: NM_008726), Myh6 (&#945;-myosin heavy chain, cardiac: NM_010856), Myh7 (&#946;-MHC: NM_080728), ColVIIIa (collagen type 8a, NM_007739), and ATP2a2 (NM_001110140.3) which encodes two Ca<sup>2+</sup>-transporting ATPase isoforms, SERCA2a (cardiac) and SERCA2b (non-muscle). SERCA2a is the predominant Ca<sup>2+</sup> pump in the myocardium (Vangheluwe et al., <xref rid="B61" ref-type="bibr">2003</xref>). All reactions were performed in triplicate and run using BIO-RAD iQ5 Multicolor Real-Time PCR Detection System with the following cycle parameters: cycle of 50&#176;C (2 min) followed by 95&#176;C (10 min), 40 cycles of 95&#176;C (15 s) followed by 60&#176;C (1 min). Raw data were analyzed using the BIO-RAD CFX Manager Software, and fold change in expression of each gene was calculated using the relative quantification (RQ) &#916;&#916;Ct method with the levels of GAPDH (glyceraldehyde-3-phosphate dehydrogenase: NM_008084) as the normalizer gene (Kazmierczak et al., <xref rid="B34" ref-type="bibr">2009</xref>).</p></sec><sec><title>Statistical analysis</title><p>All data were expressed as mean &#177; s.e.m. Statistical comparisons were performed using ANOVA or independent <italic>t</italic>-test (Sigma Plot 11; Systat Software, San Jose, CA). <italic>P</italic>-values &lt;0.05 indicated statistically significant differences.</p></sec></sec><sec sec-type="results" id="s2"><title>Results</title><sec><title>Histological evaluation of the hearts from Tg-A57G and Tg-&#916;43 mice</title><p>The evaluation performed for sedentary animals shows normal gross morphology for all tested 3&#8211;5 month-old male mice (Tg-WT, Tg-&#916;43, and Tg-A57G) (Figure <xref ref-type="fig" rid="F1">1A</xref>). In our earlier study on sedentary Tg-&#916;43 mice, we observed cardiac hypertrophy in mice ~7 months of age while the hearts of ~2 month-old Tg-&#916;43 animals were indistinguishable from control Tg-WT mice (Kazmierczak et al., <xref rid="B34" ref-type="bibr">2009</xref>). As we confirmed later, the hypertrophy in Tg-&#916;43 mice appeared to be age dependent and profound hypertrophy was observed in ~12 month-old Tg-&#916;43 mice compared with age matched Tg-WT hearts (Muthu et al., <xref rid="B46" ref-type="bibr">2011</xref>). Thus, the lack of abnormal heart growth observed in 3&#8211;5 month-old sedentary Tg-&#916;43 mice (Figure <xref ref-type="fig" rid="F1">1A</xref>), is not surprising and suggests that Tg-&#916;43 mice have to be at least 7 months of age to develop cardiac hypertrophy. Regarding sedentary Tg-A57G mice, similar to what we reported earlier (Muthu et al., <xref rid="B46" ref-type="bibr">2011</xref>), no cardiac growth could be observed in 3&#8211;5 month-old mice (Figure <xref ref-type="fig" rid="F1">1A</xref>) or the mice as old as ~12 months of age (Muthu et al., <xref rid="B46" ref-type="bibr">2011</xref>). However, exercised 3&#8211;5 month-old Tg-A57G animals do show cardiac hypertrophy while the hearts of Tg-&#916;43 mice were comparable in size to Tg-WT controls (Figure <xref ref-type="fig" rid="F1">1B</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Gross morphology of representative hearts from ~5 month-old sedentary (A) and ~3 month-old exercised (B) Tg-WT, Tg-&#916;43 and Tg-A57G male mice</bold>.</p></caption><graphic xlink:href="fphys-05-00353-g0001"/></fig><p>Histology examination of animals subjected to strenuous exercise is presented in Figure <xref ref-type="fig" rid="F2">2</xref>. H&amp;E and Masson's trichrome stained left ventricular (LV) sections from Tg-&#916;43 hearts revealed that the hearts of exercised 3&#8211;5 month-old mice demonstrated no tissue abnormalities, myofilament disarray or fibrosis compared to Tg-WT controls. In contrast, the evaluation of LV heart sections from Tg-A57G mice showed occurrences of fibrosis, especially in the interventricular septum compartment (Figure <xref ref-type="fig" rid="F2">2</xref>). This is in accord to previously reported pathological morphology in sedentary Tg-A57G mice, which included extensive disorganization of myocytes and interstitial fibrosis (Muthu et al., <xref rid="B46" ref-type="bibr">2011</xref>; Kazmierczak et al., <xref rid="B33" ref-type="bibr">2013</xref>).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>H&amp;E (upper panel) and Masson's trichrome (bottom panel) stained LV sections from exercised ~3 month-old Tg-WT, Tg-&#916;43, and Tg-A57G male mice</bold>.</p></caption><graphic xlink:href="fphys-05-00353-g0002"/></fig></sec><sec><title>Signaling pathways and changes in the gene expression profile in the hearts of two different models of hypertrophy</title><p>Hypertrophic remodeling in Tg-&#916;43 and Tg-A57G animal models was studied by looking at mutation-induced alterations in cardiac contractile proteins (&#945;- to &#946;-MHC switch), expression of the fetal genes such as ANP and BNP. We also examined whether cardiac remodeling in these mice involved changes in the calcium handling proteins such as SERCA2a. Studies of gene expression using real-time PCR in mouse myocardium were performed for sedentary and exercised Tg animals and the results are presented in Figures <xref ref-type="fig" rid="F3">3</xref>, <xref ref-type="fig" rid="F4">4</xref>, respectively. For sedentary Tg-A57G mice, the expression of sarcoplasmic ATP2a2 was higher compared with sedentary Tg-WT (~1.6 fold). The upregulation of mRNA SERCA2a in Tg-A57G mice (Figure <xref ref-type="fig" rid="F3">3</xref>) may translate to a faster relaxation of the A57G myosin cross-bridges and potentially lower contractile force generation in Tg-A57G mice, what is actually observed (Figure <xref ref-type="fig" rid="F5">5A</xref>). For sedentary Tg-&#916;43 mice the expression levels of ANP and BNP were higher compared with sedentary Tg-WT (2- and 2.4 fold, respectively) (Figure <xref ref-type="fig" rid="F3">3</xref>).</p><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>QPCR data for sedentary ELC animals</bold>. Sedentary Tg-WT was used as a control sample (FC = 1); <sup>*</sup>indicates <italic>P</italic> &lt; 0.05 compared to sedentary Tg-WT.</p></caption><graphic xlink:href="fphys-05-00353-g0003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><p><bold>QPCR data for exercised ELC animals</bold>. Exercised Tg-WT is used as a control sample (FC = 1); <sup>*</sup>indicates <italic>P</italic> &lt; 0.05 compared to exercised Tg-WT mice.</p></caption><graphic xlink:href="fphys-05-00353-g0004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><p><bold>Measurements of steady-state force in skinned papillary muscle strips from sedentary and exercised transgenic ELC male mice. (A)</bold> Maximal force assessment at pCa4. <bold>(B)</bold> Calcium sensitivity of force.</p></caption><graphic xlink:href="fphys-05-00353-g0005"/></fig><p>This upregulation of both natriuretic peptides in Tg-&#916;43 mice most likely manifests their protective role against excessive cardiac remodeling and preventing uncontrolled myocardial growth of Tg-&#916;43 hearts (Tsuruda et al., <xref rid="B59" ref-type="bibr">2002</xref>; Gardner, <xref rid="B18" ref-type="bibr">2003</xref>).</p><p>To evaluate a combined effect of strenuous exercise and ELC mutation on heart remodeling we have also studied the molecular mechanisms and signaling pathways that change due to exercise. Figure <xref ref-type="fig" rid="F4">4</xref> presents the gene expression analysis using real-time PCR in mouse myocardium performed for exercised Tg ELC animals. In Tg-A57G mice the exercise training reactivated the fetal gene program and upregulation in the &#946;-MHC, ANP and BNP was observed. Expression of ANP and BNP was respectively 1.9- and 2.1 fold higher compared with exercised Tg-WT (both differences statistically significant <italic>P</italic> &lt; 0.05). Additionally, upregulation of collagen VIIIa (1.9 fold change, significant <italic>P</italic> &lt; 0.05) and &#946;-MHC (not significant) and downregulation of &#945;-MHC was observed for exercised Tg-A57G compared with exercised Tg-WT mice (Figure <xref ref-type="fig" rid="F4">4</xref>). On the other hand, exercised Tg-&#916;43 mice showed a 0.6-fold lower expression level of ANP (<italic>P</italic> &lt; 0.05) and no change in BNP marker compared to exercised Tg-WT controls (Figure <xref ref-type="fig" rid="F4">4</xref>). Changes in gene expression observed in Tg-A57G mice in response to strenuous exercise represent a pathologic type of remodeling occurring in the disease mouse model. In contrast, lack of changes in expression levels of BNP, &#946;-MHC and collagen VIIIa in exercised Tg-&#916;43 mice represents an adaptive response to exercise and non-pathological remodeling in Tg-&#916;43 animals.</p></sec><sec><title>Steady-state force measurements and Ca<sup>2+</sup> dependence of force development</title><p>The data from functional measurements assessed in skinned mouse papillary muscle strips from Tg-&#916;43 and Tg-A57G animals are presented in Figure <xref ref-type="fig" rid="F5">5</xref>, and the values of maximal force and pCa<sub>50</sub> are summarrized in Table <xref ref-type="table" rid="T1">1</xref>. Different pattern of contractile force generation and the Ca<sup>2+</sup> sensitivity of force was observed betweenTg-A57G and Tg-&#916;43 mice. Similar to our earlier study (Kazmierczak et al., <xref rid="B33" ref-type="bibr">2013</xref>), sedentary Tg-A57G mice showed the lowest maximal force (~20% lower vs. sedentary Tg-WT) and a slightly increased Ca<sup>2+</sup> sensitivity of force (&#916;pCa<sub>50</sub> &#8773;0.04 vs. sedentary Tg-WT), both changes statistically significant. As we demonstrated earlier and in this study, sedentary Tg-A57G animals showed reduced maximal (pCa 4) force and increased Ca<sup>2+</sup> sensitivity following the pattern of pathological hypertrophy (Muthu et al., <xref rid="B46" ref-type="bibr">2011</xref>; Kazmierczak et al., <xref rid="B33" ref-type="bibr">2013</xref>) (Figures <xref ref-type="fig" rid="F5">5</xref>, <xref ref-type="fig" rid="F6">6</xref>). Contrary, maximal force for sedentary Tg-&#916;43 mice was similar to that of Tg-WT and the Ca<sup>2+</sup> sensitivity was not changed (&#916;pCa<sub>50</sub> &#8773;0.02; not statistically significant) compared to Tg-WT controls. The previously reported reduction in steady-state force in ~2 month-old and ~7 month-old Tg-&#916;43 mice (Kazmierczak et al., <xref rid="B34" ref-type="bibr">2009</xref>) was likely associated with a decrease in the myosin content observed in these animals vs. the lack of changes in myosin expression seen in the current investigation (Figure <xref ref-type="fig" rid="F7">7</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p><bold>Maximal pCa 4 force and calcium sensitivity of force in transgenic ELC skinned mouse papillary muscle strips</bold>.</p></caption><table-wrap-foot><p>Data are mean &#177; SEM of n = 8&#8211;15 individual strips for each group of mice.</p></table-wrap-foot></table-wrap><fig id="F6" position="float"><label>Figure 6</label><caption><p><bold>The force- pCa relationship in transgenic skinned mouse papillary muscle strips from Tg-WT, Tg-&#916;43, and Tg-A57G male mice</bold>.</p></caption><graphic xlink:href="fphys-05-00353-g0006"/></fig><fig id="F7" position="float"><label>Figure 7</label><caption><p><bold>Thick and thin filament protein content in sedentary and exercised Tg-&#916;43 and Tg-A57G mice compared to control Tg-WT</bold>.</p></caption><graphic xlink:href="fphys-05-00353-g0007"/></fig><p>In response to exercise, all transgenic animals showed a higher level of maximal force per cross-section of muscle strip vs. their sedentary controls (Table <xref ref-type="table" rid="T1">1</xref>). Similarly to the direction of changes observed for sedentary animals, in response to swimming, the maximal force for Tg-&#916;43 was similar while that for Tg-A57G was significantly reduced (~20% lower, <italic>P</italic> &lt; 0.005) compared to exercised Tg-WT. Additionally, for exercised Tg-A57G, the Ca<sup>2+</sup> sensitivity of force was significantly lower compared to sedentary Tg-A57G mice (&#916;pCa<sub>50</sub> &#8773;0.08) (Figures <xref ref-type="fig" rid="F5">5B</xref>, <xref ref-type="fig" rid="F6">6</xref> and Table <xref ref-type="table" rid="T1">1</xref>). Tendency toward desensitization of myofilaments to Ca<sup>2+</sup> observed in Tg-A57G mice (Table <xref ref-type="table" rid="T1">1</xref>) may represent a key step in the signaling pathway for the pathological hypertrophic remodeling in this animal model of HCM. As expected, there were no significant changes in the Ca<sup>2+</sup> sensitivity of force between exercised and sedentary Tg-WT mice. Likewise, no significant changes in the Ca<sup>2+</sup> sensitivity were present between the exercised and sedentary Tg-&#916;43 mice (Table <xref ref-type="table" rid="T1">1</xref>). No changes in the cooperativity (Hill coefficient) values for all groups of mice (n<sub>H</sub> = 2.6 &#177; 0.3) were noted (Figure <xref ref-type="fig" rid="F6">6</xref>).</p></sec><sec><title>Assessment of myosin content in sedentary and exercised animals</title><p>As mentioned above, the reduced level of maximal contractile force measured in our previous study for sedentary Tg-&#916;43 mice was most likely associated with deficiency in myosin content detected in the myocardium of Tg-&#916;43 vs. Tg-WT mice (Kazmierczak et al., <xref rid="B34" ref-type="bibr">2009</xref>). Therefore, myosin content in sedentary and exercised animals was assessed in this study and correlated with the ability of the myocardium to develop contractile force. Figure <xref ref-type="fig" rid="F7">7</xref> presents the ratios of RLC<sub>tot.</sub>/Tm and RLC<sub>tot.</sub>/TnI determined in cardiac myofibrillar preparations from sedentary and exercised Tg-WT, Tg-A57G, and Tg-&#916;43 mice. Compared to respective Tg-WT myofibrils (100%), the ratios of RLC<sub>tot.</sub>/Tm and RLC<sub>tot.</sub>/TnI obtained for sedentary and exercised Tg-A57G mice were similar to Tg-WT indicating no change in myosin expression in all tested animals (Figure <xref ref-type="fig" rid="F7">7</xref>). Therefore, the lower maximal force observed for the A57G mutation in this study is not due to the lower myosin content but due to defective function of the A57G-myocardium. The values of RLC<sub>tot.</sub>/Tm and RLC<sub>tot.</sub>/TnI ratios obtained for sedentary and exercised Tg-&#916;43 mice were also very similar to Tg-WT (~110%), indicating no previously observed deficiency of myosin in the hearts of Tg-&#916;43 animals (Kazmierczak et al., <xref rid="B34" ref-type="bibr">2009</xref>).</p></sec><sec><title>Myofilament protein phosphorylation in sedentary and exercised mice</title><p>The force-generating capacity of sarcomeres has been known to be tightly regulated by sarcomeric proteins phosphorylation (Sweeney et al., <xref rid="B55" ref-type="bibr">1993</xref>; Sadayappan et al., <xref rid="B51" ref-type="bibr">2009</xref>; Nixon et al., <xref rid="B48" ref-type="bibr">2012</xref>). To test whether the ELC mutation (&#916;43 or A57G) and/or exercise had any effect on phosphorylation of sarcomeric proteins, we have examined phosphorylation of myosin binding protein C (MyBP-C), Tm, troponin (TnT and TnI) and myosin RLC in mouse cardiac myofibrils using the Pro-Q Diamond staining. As shown in Figure <xref ref-type="fig" rid="F8">8</xref>, no significant changes in endogenous MyBP-C, Tm, TnT, TnI, or RLC phosphorylation were found in sedentary or exercised Tg-&#916;43 or Tg-A57G animals compared to Tg-WT mice. The lack of the effect of exercise on protein phosphorylation is somewhat surprising but has been observed by other laboratories. No effect of exercise on phosphorylation of myosin RLC in the ventricles or atria of mice was found by Fewell et al. (<xref rid="B16" ref-type="bibr">1997</xref>). Likewise, no changes in phosphorylation of titin and TnI in mice upon exercise training were recently reported by the Granzier group (Hidalgo et al., <xref rid="B23" ref-type="bibr">2014</xref>). These results suggest no immediate molecular contacts between the ELC protein and the phosphorylation domains of MyBP-C, Tm, TnT, TnI, or RLC.</p><fig id="F8" position="float"><label>Figure 8</label><caption><p><bold>Assessment of protein phosphorylation in sedentary and exercised Tg-WT, Tg-&#916;43, and Tg-A57G mouse myofibrils</bold>. MyBP-C, myosin binding protein C; TnT, troponin T; Tm, tropomyosin; TnI, troponin I; RLC, myosin regulatory light chain; ELC<sub>end</sub>, myosin ELC (all mouse isoforms); ELC<sub>Tg</sub>, transgenic human ELC; +P hc std, phosphorylated human cardiac protein standard.</p></caption><graphic xlink:href="fphys-05-00353-g0008"/></fig></sec></sec><sec sec-type="discussion" id="s3"><title>Discussion</title><p>Hypertrophic remodeling is a highly important phenomenon; however, the molecular mechanisms and signaling pathways underlying these processes have not yet been fully understood. In particular, molecular pathways that play a causal role in the development of pathological vs. physiological hypertrophy need to be recognized due to the known association between cardiac hypertrophy and nearly all forms of heart failure (Levy et al., <xref rid="B38" ref-type="bibr">1990</xref>). Recognition of functional, structural, metabolic, and molecular differences between pathological and non-pathological hypertrophy may help to develop potential therapeutic approaches to benefit patients with HCM and heart failure.</p><sec><title>Remodeling in sedentary mice</title><p>Since the ELC is a highly essential element of the myosin molecule, its structure and the interaction with the MHC and actin play important roles in the sarcomeric assembly and force production (Hernandez et al., <xref rid="B22" ref-type="bibr">2007</xref>). This investigation was designed to look at two different cardiac phenotypes induced by structural alterations in the myosin ELC in mouse models of pathologic (Tg-A57G) and physiologic (Tg-&#916;43) HCM. The effects of both ELC mutations on heart function and cardiac remodeling are summarized in Figure <xref ref-type="fig" rid="F9">9</xref>. Data obtained for sedentary and exercised Tg-A57G and Tg-&#916;43 animals show clear differences between these two phenotypes. Consistent with our earlier reports, we monitored significantly compromised contractile function (lower maximal force and higher Ca<sup>2+</sup> sensitivity) in sedentary Tg-A57G mice, which coincided with upregulation of the calcium handling protein SERCA2a compared to sedentary Tg-WT animals. It has been reported that in animal models, severe compensated hypertrophy in response to pressure overload is accompanied by a large decrease in the mRNA and protein content of SERCA2a (Buttrick et al., <xref rid="B9" ref-type="bibr">1994</xref>; Rockman et al., <xref rid="B50" ref-type="bibr">1994</xref>). However, in rats with moderate cardiac hypertrophy, the level of SERCA2a mRNA or protein was unaltered or even upregulated (Rockman et al., <xref rid="B50" ref-type="bibr">1994</xref>; Arai et al., <xref rid="B4" ref-type="bibr">1996</xref>). SERCA2a is a key protein responsible for maintaining a balanced concentration of Ca<sup>2+</sup> during the cardiac cycle and it controls the transport of Ca<sup>2+</sup> to the SR during relaxation. The upregulation of mRNA SERCA2a in Tg-A57G mice (Figure <xref ref-type="fig" rid="F3">3</xref>) may translate to an increased protein activity, which would lead to faster relaxation of the A57G myosin cross-bridges and potentially lower contractile force generation in Tg-A57G myocardium (Figure <xref ref-type="fig" rid="F5">5A</xref>).</p><fig id="F9" position="float"><label>Figure 9</label><caption><p><bold>Molecular effects of A57G and &#916;43 mutations in the myosin ELC on heart morphology and function and expression of hypertrophic markers in sedentary and exercised Tg ELC mice</bold>. All data are compared with either sedentary or exercised Tg-WT ELC. The <italic>in vivo</italic> data were published previously. LVV, LV-volume; CO, cardiac output; SW, stroke work; LVEDV, LV-end diastolic volume; E<sub>es</sub>, measure of myocardial contractility defined by the slope of the end-systolic pressure-volume relationship.</p></caption><graphic xlink:href="fphys-05-00353-g0009"/></fig><p>These adverse effects were not present in sedentary Tg-&#916;43 mice, the model of non-pathological cardiac phenotype. The maximal force and Ca<sup>2+</sup> sensitivity values were similar to those determined for sedentary Tg-WT mice, indicating a normal heart function in Tg-&#916;43 animals. As we reported earlier (Kazmierczak et al., <xref rid="B34" ref-type="bibr">2009</xref>, <xref rid="B33" ref-type="bibr">2013</xref>; Muthu et al., <xref rid="B46" ref-type="bibr">2011</xref>) both mouse models demonstrated cardiac hypertrophic growth, but the pathological features were only observed in sedentary A57G animals (Kazmierczak et al., <xref rid="B34" ref-type="bibr">2009</xref>; Muthu et al., <xref rid="B46" ref-type="bibr">2011</xref>; Kazmierczak et al., <xref rid="B33" ref-type="bibr">2013</xref>). Discrepancies exist regarding the lack of reduction in maximal force observed in Tg-&#916;43 mice in the current study (Table <xref ref-type="table" rid="T1">1</xref>) and the previously reported decrease in steady-state force in Tg-&#916;43 mice (Kazmierczak et al., <xref rid="B34" ref-type="bibr">2009</xref>). The reason for a lower force reported in Kazmierczak et al. (<xref rid="B34" ref-type="bibr">2009</xref>) was an approximately 30% deficit in myosin cross-bridge content in the myocardium of Tg-&#916;43 mice (Kazmierczak et al., <xref rid="B34" ref-type="bibr">2009</xref>). This deficit in myosin content was not observed in the current work (Figure <xref ref-type="fig" rid="F7">7</xref>), indicating a compensatory response in transgenic Tg-&#916;43 mice over time. Consequently, the lack of abnormalities in myosin expression was most likely responsible for no changes in force per cross-section of muscle seen in Tg-&#916;43 mice in the current investigation (Table <xref ref-type="table" rid="T1">1</xref>). Additionaly, recently published data utilizing the same Tg-&#916;43 mouse model, showed only a slight (and not significant) decrease in maximal tension between Tg-WT and Tg-&#916;43 (Michael et al., <xref rid="B40" ref-type="bibr">2013</xref>; Wang et al., <xref rid="B62" ref-type="bibr">2013a</xref>).</p><p>Sedentary Tg-&#916;43 mice also showed an upregulation of ANP and BNP (Figure <xref ref-type="fig" rid="F3">3</xref>). Upregulation of these transcripts is considered a highly conserved feature of ventricular hypertrophy (Lee et al., <xref rid="B35" ref-type="bibr">1988</xref>; Dagnino et al., <xref rid="B12" ref-type="bibr">1992</xref>; Buttrick et al., <xref rid="B9" ref-type="bibr">1994</xref>; Nakagawa et al., <xref rid="B47" ref-type="bibr">1995</xref>), but there are contradictory reports in the literature on the correlation of upregulation of natriuretic peptides with physiological hypertrophy that can be induced by various training programs in animals. Some publications report an upregulation (Buttrick et al., <xref rid="B9" ref-type="bibr">1994</xref>; Allen et al., <xref rid="B3" ref-type="bibr">2001</xref>), while some report no change (Azizi et al., <xref rid="B6" ref-type="bibr">1995</xref>; Jin et al., <xref rid="B31" ref-type="bibr">2000</xref>) or downregulation (Diffee et al., <xref rid="B13" ref-type="bibr">2003</xref>) of ANP and/or BNP expression in these animal models. Both natriuretic peptides were shown to function as modulators of cardiac hypertrophy preventing uncontrolled myocardial growth and regulating ventricular remodeling secondary to compensatory hypertrophy (Tsuruda et al., <xref rid="B59" ref-type="bibr">2002</xref>; Gardner, <xref rid="B18" ref-type="bibr">2003</xref>). It is therefore possible that in the case of sedentary Tg-&#916;43 mice, mild upregulation of ANP and BNP manifests their protective role against excessive cardiac remodeling and controlling the extent of cardiac hypertrophy.</p><p>There are some discrepancies between our earlier study and current investigation on the hypertrophic growth in sedentary Tg-&#916;43 mice. In Kazmierczak et al. (<xref rid="B34" ref-type="bibr">2009</xref>), we presented the gross morphology images of young (~2 mo-old) and adult (~7 mo-old) Tg-&#916;43 animals. The hypertrophy was only noted for the older animals. The hearts of young Tg-&#916;43 mice were indistinguishable from age matched control Tg-WT mice. In the current study, the hearts of 3&#8211;5 month-old sedentary Tg-&#916;43 mice were not much different than those of age matched Tg-WT controls (Figure <xref ref-type="fig" rid="F1">1A</xref>). These data suggest that hypertrophy in Tg-&#916;43 mice is an age dependent process and the fact that it was not present in &lt;5 month-old Tg-&#916;43 animals (Figure <xref ref-type="fig" rid="F1">1A</xref>), i.e., ~2 months before the apparent threshold when the animals reach ~7 months of age (Kazmierczak et al., <xref rid="B34" ref-type="bibr">2009</xref>) is not surprising. In line with this, a profound hypertrophy in ~12 month-old Tg-&#916;43 mice was recently reported by our group (Muthu et al., <xref rid="B46" ref-type="bibr">2011</xref>).</p></sec><sec><title>Remodeling in exercised mice</title><p>Swimming exercise is known for its efficiency in inducing cardiac hypertrophy and significant increases in LV end-diastolic volumes in rats (Geenen et al., <xref rid="B19" ref-type="bibr">1988</xref>). We hypothesized that strenuous exercise applied to Tg-&#916;43 and Tg-A57G mice would lead to differential cardiac remodeling in these animal models displaying two distinct phenotypes of a &#8220;healthy&#8221; (&#916;43) vs. &#8220;diseased&#8221; (A57G) heart. Our data on exercised animals confirmed our hypothesis. For Tg-A57G animals, we observed a significant upregulation of hypertrophic markers that were activated upon exercise initiating pathological hypertrophic remodeling in Tg-A57G mice (Figure <xref ref-type="fig" rid="F9">9</xref>). Upregulation of ANP and BNP transcripts observed in exercised Tg-A57G mice (Figure <xref ref-type="fig" rid="F4">4</xref>) manifests their sensitivity in monitoring ventricular hypertrophy (Lee et al., <xref rid="B35" ref-type="bibr">1988</xref>; Dagnino et al., <xref rid="B12" ref-type="bibr">1992</xref>; Nakagawa et al., <xref rid="B47" ref-type="bibr">1995</xref>). ANP and BNP are released by the heart usually in response to heart failure (cardiac injury). The BNP levels in plasma have been shown to be useful in monitoring therapy for heart failure and typically a good response to effective treatment correlates with decreased concentrations of BNP (Lee et al., <xref rid="B36" ref-type="bibr">2002</xref>; Yoshimura et al., <xref rid="B68" ref-type="bibr">2002</xref>). Upregulation of ANP, BNP, and Collagen VIIIa was paralleled by a visible increase in heart size in Tg-A57G mice (Figure <xref ref-type="fig" rid="F1">1B</xref>), manifesting pathological hypertrophic remodeling in Tg-A57G mice (Figure <xref ref-type="fig" rid="F9">9</xref>).</p><p>Force generation and the Ca<sup>2+</sup> sensitivity of force in Tg-A57G mice were significantly reduced after strenuous excise (Tables <xref ref-type="table" rid="T1">1</xref>, <xref ref-type="table" rid="T2">2</xref>) manifesting pathological hypertrophic remodeling. Although maximal force in these animals was slightly improved compared to sedentary mice it was still significantly lower than that monitored for other exercised mice. It is possible that strenuous exercise caused activation of the &#946;-adrenergic pathway in Tg-A57G hearts that could lead to compromised heart performance. Decreased Ca<sup>2+</sup> sensitivity in these animals compared to sedentary Tg-A57G mice might be indicative of progressing toward heart failure as observed in animal models of HF (Cazorla et al., <xref rid="B11" ref-type="bibr">2005</xref>; Belin et al., <xref rid="B7" ref-type="bibr">2007</xref>) and in humans (Van Dijk et al., <xref rid="B60" ref-type="bibr">2009</xref>; Hoskins et al., <xref rid="B27" ref-type="bibr">2010</xref>; Sequeira et al., <xref rid="B53" ref-type="bibr">2013</xref>; Witjas-Paalberends et al., <xref rid="B66" ref-type="bibr">2013</xref>). The presence of collagen deposits in the myocardium of Tg-A57G mice (Figure <xref ref-type="fig" rid="F2">2</xref>) indicates the propensity of the heart to increase its LV stiffness that ultimately may result in diastolic dysfunction in Tg-A57G mice (Wu et al., <xref rid="B67" ref-type="bibr">2007</xref>).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p><bold>Statistics for measurements of steady-state force in skinned papillary muscle strips from sedentary and exercised transgenic ELC animals</bold>.</p></caption></table-wrap><p>A different response on the strenuous exercise was observed for the second Tg-&#916;43 animal model. Function of the heart remained normal and both maximal force and the Ca<sup>2+</sup> sensitivity were similar to exercised Tg-WT mice. Additionally, exercised Tg-&#916;43 animals showed similar pattern of gene expression to that observed in exercised Tg-WT mice, indicating that hypertrophic remodeling of the heart was no longer present in this animal model. The lack of changes in expression levels of BNP, &#946;-MHC, and collagen VIIIa in exercised Tg-&#916;43 mice represents an adaptive response to exercise and non-pathological remodeling in Tg-&#916;43 animals compared to detrimental heart remodeling observed in exercised Tg-A57G mice.</p></sec></sec><sec><title>Conclusive remarks</title><p>Our previous X-ray studies on sedentary Tg-A57G and Tg-&#916;43 mice demonstrated a mutation-induced decrease in the filament lattice spacing in skinned papillary muscles of Tg-A57G compared to Tg-WT controls (Muthu et al., <xref rid="B46" ref-type="bibr">2011</xref>). These structural changes may initiate hypertrophic remodeling of the heart triggered by mutation-induced conformational changes within the sarcomere that lead to abnormal interaction of two major contractile proteins, myosin and actin causing abnormalities in contractile force production and heart performance. Pathological ventricular remodeling and anatomical changes observed in Tg-A57G hearts mostly develop in older animals and, as we anticipated, they were augmented in response to strenuous exercise. In contrast, X-ray diffraction studies on Tg-&#916;43 mice demonstrated a shift of cross-bridge mass from the thick filament backbone toward the thin filaments and no changes in the interfilament spacing compared with Tg-WT controls (Muthu et al., <xref rid="B46" ref-type="bibr">2011</xref>). These data indicate that the lack of the N-terminal ELC extension in Tg-&#916;43 animals may lead to changes in myosin head orientation positioning it closer (at smaller angle) to the actin filaments (Muthu et al., <xref rid="B46" ref-type="bibr">2011</xref>). The important function of the N-terminal extension of the ELC protein was also demonstrated in other study showing that the length-dependent activation in Tg-&#916;43 strips was blunted in Tg-&#916;43 animals (Michael et al., <xref rid="B40" ref-type="bibr">2013</xref>). This could eventually lead to hypertrophy in Tg-&#916;43 animals but of the non-pathological nature.</p><p>Combined knowledge of the genetic basis of HCM with biophysical and transcriptional analyses may help to better understand the pathophysiology of heart remodeling and make predictive correlations between the specific mutations with disease prognosis. The heart may tolerate various types of stimuli, but compensatory/adaptive responses that aim to maintain function may fail in case of patients with pre-existing HCM (hearts with disease-causing mutations), resulting in a wide range of functional deficits and/or cardiomyopathy. The strenuous exercise of competitive athletes has been known to make symptoms of HCM more apparent and because of the risk of SCD during exercise, HCM patients are excluded from most competitive sports (Michels et al., <xref rid="B41" ref-type="bibr">2009</xref>). Our data confirm that it is reasonable to caution people with diagnosed genetic HCM against intensive exercise programs. Our previous and current studies suggest that the A57G mutation can initiate pathologic cardiac remodeling and drive the heart toward cardiomyopathy disease and/or heart failure while the &#916;43&#8211;dependent pathway displays a tendency toward a non-pathological cardiac phenotype.</p></sec><sec><title>Author contributions</title><p>Katarzyna Kazmierczak, Conception and design of research, execution of experiments, analysis and interpretation of data, figure preparation, drafting of the manuscript. Chen-ching Yuan, Execution of experiments, analysis of data. Jingsheng Liang, Execution of experiments, analysis of data. Wenrui Huang, Execution of experiments, analysis of data, figure preparation. Ana I. Rojas, Breeding mouse colonies and <italic>in vivo</italic> data collection. Danuta Szczesna-Cordary, Conception and design of research, analysis and interpretation of data, figure preparation, drafting of the manuscript.</p></sec><sec><title>Funding</title><p>This work was supported by the National Institutes of Health Grants R01 HL-108343 and HL-071778 (to DSC).</p><sec><title>Conflict of interest statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></sec></body><back><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abel</surname><given-names>E. D.</given-names></name><name><surname>Doenst</surname><given-names>T.</given-names></name></person-group> (<year>2011</year>). <article-title>Mitochondrial adaptations to physiological vs. pathological cardiac hypertrophy</article-title>. <source>Cardiovasc. Res</source>. <volume>90</volume>, <fpage>234</fpage>&#8211;<lpage>242</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvr015</pub-id><?supplied-pmid 21257612?><pub-id pub-id-type="pmid">21257612</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alcalai</surname><given-names>R.</given-names></name><name><surname>Seidman</surname><given-names>J. G.</given-names></name><name><surname>Seidman</surname><given-names>C. E.</given-names></name></person-group> (<year>2008</year>). <article-title>Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics</article-title>. <source>J. Cardiovasc. Electrophysiol</source>. <volume>19</volume>, <fpage>104</fpage>&#8211;<lpage>110</lpage>
<pub-id pub-id-type="doi">10.1097/HCO.0b013e3283375698</pub-id><?supplied-pmid 17916152?><pub-id pub-id-type="pmid">17916152</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>D. L.</given-names></name><name><surname>Harrison</surname><given-names>B. C.</given-names></name><name><surname>Maass</surname><given-names>A.</given-names></name><name><surname>Bell</surname><given-names>M. L.</given-names></name><name><surname>Byrnes</surname><given-names>W. C.</given-names></name><name><surname>Leinwand</surname><given-names>L. A.</given-names></name></person-group> (<year>2001</year>). <article-title>Cardiac and skeletal muscle adaptations to voluntary wheel running in the mouse</article-title>. <source>J. Appl. Physiol. (1985)</source>
<volume>90</volume>, <fpage>1900</fpage>&#8211;<lpage>1908</lpage>
<?supplied-pmid 11299284?><pub-id pub-id-type="pmid">11299284</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arai</surname><given-names>M.</given-names></name><name><surname>Suzuki</surname><given-names>T.</given-names></name><name><surname>Nagai</surname><given-names>R.</given-names></name></person-group> (<year>1996</year>). <article-title>Sarcoplasmic reticulum genes are upregulated in mild cardiac hypertrophy but downregulated in severe cardiac hypertrophy induced by pressure overload</article-title>. <source>J. Mol. Cell. Cardiol</source>. <volume>28</volume>, <fpage>1583</fpage>&#8211;<lpage>1590</lpage>
<pub-id pub-id-type="doi">10.1006/jmcc.1996.0149</pub-id><?supplied-pmid 8877769?><pub-id pub-id-type="pmid">8877769</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aydt</surname><given-names>E. M.</given-names></name><name><surname>Wolff</surname><given-names>G.</given-names></name><name><surname>Morano</surname><given-names>I.</given-names></name></person-group> (<year>2007</year>). <article-title>Molecular modeling of the myosin-S1(A1) isoform</article-title>. <source>J. Struct. Biol</source>. <volume>159</volume>, <fpage>158</fpage>&#8211;<lpage>163</lpage>
<pub-id pub-id-type="doi">10.1016/j.jsb.2007.04.002</pub-id><?supplied-pmid 17498971?><pub-id pub-id-type="pmid">17498971</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azizi</surname><given-names>C.</given-names></name><name><surname>Bouissou</surname><given-names>P.</given-names></name><name><surname>Galen</surname><given-names>F. X.</given-names></name><name><surname>Lattion</surname><given-names>A. L.</given-names></name><name><surname>Lartigue</surname><given-names>M.</given-names></name><name><surname>Carayon</surname><given-names>A.</given-names></name></person-group> (<year>1995</year>). <article-title>Alterations in atrial natriuretic peptide gene expression during endurance training in rats</article-title>. <source>Eur. J. Endocrinol</source>. <volume>133</volume>, <fpage>361</fpage>&#8211;<lpage>365</lpage>
<pub-id pub-id-type="doi">10.1530/eje.0.1330361</pub-id><?supplied-pmid 7581955?><pub-id pub-id-type="pmid">7581955</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belin</surname><given-names>R. J.</given-names></name><name><surname>Sumandea</surname><given-names>M. P.</given-names></name><name><surname>Allen</surname><given-names>E. J.</given-names></name><name><surname>Schoenfelt</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Solaro</surname><given-names>R. J.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Augmented protein kinase C-alpha-induced myofilament protein phosphorylation contributes to myofilament dysfunction in experimental congestive heart failure</article-title>. <source>Circ. Res</source>. <volume>101</volume>, <fpage>195</fpage>&#8211;<lpage>204</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.107.148288</pub-id><?supplied-pmid 17556659?><pub-id pub-id-type="pmid">17556659</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernardo</surname><given-names>B. C.</given-names></name><name><surname>Weeks</surname><given-names>K. L.</given-names></name><name><surname>Pretorius</surname><given-names>L.</given-names></name><name><surname>McMullen</surname><given-names>J. R.</given-names></name></person-group> (<year>2010</year>). <article-title>Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies</article-title>. <source>Pharmacol. Ther</source>. <volume>128</volume>, <fpage>191</fpage>&#8211;<lpage>227</lpage>
<pub-id pub-id-type="doi">10.1016/j.pharmthera.2010.04.005</pub-id><?supplied-pmid 20438756?><pub-id pub-id-type="pmid">20438756</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buttrick</surname><given-names>P. M.</given-names></name><name><surname>Kaplan</surname><given-names>M.</given-names></name><name><surname>Leinwand</surname><given-names>L. A.</given-names></name><name><surname>Scheuer</surname><given-names>J.</given-names></name></person-group> (<year>1994</year>). <article-title>Alterations in gene expression in the rat heart after chronic pathological and physiological loads</article-title>. <source>J. Mol. Cell. Cardiol</source>. <volume>26</volume>, <fpage>61</fpage>&#8211;<lpage>67</lpage>
<pub-id pub-id-type="doi">10.1006/jmcc.1994.1008</pub-id><?supplied-pmid 8196070?><pub-id pub-id-type="pmid">8196070</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cadete</surname><given-names>V. J.</given-names></name><name><surname>Sawicka</surname><given-names>J.</given-names></name><name><surname>Jaswal</surname><given-names>J. S.</given-names></name><name><surname>Lopaschuk</surname><given-names>G. D.</given-names></name><name><surname>Schulz</surname><given-names>R.</given-names></name><name><surname>Szczesna-Cordary</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Ischemia/reperfusion-induced myosin light chain 1 phosphorylation increases its degradation by matrix metalloproteinase 2</article-title>. <source>FEBS J</source>. <volume>279</volume>, <fpage>2444</fpage>&#8211;<lpage>2454</lpage>
<pub-id pub-id-type="doi">10.1111/j.1742-4658.2012.08622.x</pub-id><?supplied-pmid 22564771?><pub-id pub-id-type="pmid">22564771</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cazorla</surname><given-names>O.</given-names></name><name><surname>Szilagyi</surname><given-names>S.</given-names></name><name><surname>Le Guennec</surname><given-names>J. Y.</given-names></name><name><surname>Vassort</surname><given-names>G.</given-names></name><name><surname>Lacampagne</surname><given-names>A.</given-names></name></person-group> (<year>2005</year>). <article-title>Transmural stretch-dependent regulation of contractile properties in rat heart and its alteration after myocardial infarction</article-title>. <source>FASEB J</source>. <volume>19</volume>, <fpage>88</fpage>&#8211;<lpage>90</lpage>
<pub-id pub-id-type="doi">10.1096/fj.04-2066fje</pub-id><?supplied-pmid 15498894?><pub-id pub-id-type="pmid">15498894</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dagnino</surname><given-names>L.</given-names></name><name><surname>Lavigne</surname><given-names>J. P.</given-names></name><name><surname>Nemer</surname><given-names>M.</given-names></name></person-group> (<year>1992</year>). <article-title>Increased transcripts for B-type natriuretic peptide in spontaneously hypertensive rats. Quantitative polymerase chain reaction for atrial and brain natriuretic peptide transcripts</article-title>. <source>Hypertension</source>
<volume>20</volume>, <fpage>690</fpage>&#8211;<lpage>700</lpage>
<pub-id pub-id-type="doi">10.1161/01.HYP.20.5.690</pub-id><?supplied-pmid 1385327?><pub-id pub-id-type="pmid">1385327</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diffee</surname><given-names>G. M.</given-names></name><name><surname>Seversen</surname><given-names>E. A.</given-names></name><name><surname>Stein</surname><given-names>T. D.</given-names></name><name><surname>Johnson</surname><given-names>J. A.</given-names></name></person-group> (<year>2003</year>). <article-title>Microarray expression analysis of effects of exercise training: increase in atrial MLC-1 in rat ventricles</article-title>. <source>Am. J. Physiol. Heart Circ. Physiol</source>. <volume>284</volume>, <fpage>H830</fpage>&#8211;<lpage>H837</lpage>
<pub-id pub-id-type="doi">10.1152/ajpheart.00761.2002</pub-id><?supplied-pmid 12424097?><pub-id pub-id-type="pmid">12424097</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dweck</surname><given-names>D.</given-names></name><name><surname>Reyes-Alfonso</surname><given-names>A.</given-names><suffix>Jr.</suffix></name><name><surname>Potter</surname><given-names>J. D.</given-names></name></person-group> (<year>2005</year>). <article-title>Expanding the range of free calcium regulation in biological solutions</article-title>. <source>Anal. Biochem</source>. <volume>347</volume>, <fpage>303</fpage>&#8211;<lpage>315</lpage>
<pub-id pub-id-type="doi">10.1016/j.ab.2005.09.025</pub-id><?supplied-pmid 16289079?><pub-id pub-id-type="pmid">16289079</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evangelista</surname><given-names>F. S.</given-names></name><name><surname>Brum</surname><given-names>P. C.</given-names></name><name><surname>Krieger</surname><given-names>J. E.</given-names></name></person-group> (<year>2003</year>). <article-title>Duration-controlled swimming exercise training induces cardiac hypertrophy in mice</article-title>. <source>Braz. J. Med. Biol. Res</source>. <volume>36</volume>, <fpage>1751</fpage>&#8211;<lpage>1759</lpage>
<pub-id pub-id-type="doi">10.1590/S0100-879X2003001200018</pub-id><?supplied-pmid 14666261?><pub-id pub-id-type="pmid">14666261</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fewell</surname><given-names>J. G.</given-names></name><name><surname>Osinska</surname><given-names>H.</given-names></name><name><surname>Klevitsky</surname><given-names>R.</given-names></name><name><surname>Ng</surname><given-names>W.</given-names></name><name><surname>Sfyris</surname><given-names>G.</given-names></name><name><surname>Bahrehmand</surname><given-names>F.</given-names></name><etal/></person-group> (<year>1997</year>). <article-title>A treadmill exercise regimen for identifying cardiovascular phenotypes in transgenic mice</article-title>. <source>Am. J. Physiol</source>. <volume>273</volume>, <fpage>H1595</fpage>&#8211;<lpage>H1605</lpage>
<?supplied-pmid 9321854?><pub-id pub-id-type="pmid">9321854</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galindo</surname><given-names>C. L.</given-names></name><name><surname>Skinner</surname><given-names>M. A.</given-names></name><name><surname>Errami</surname><given-names>M.</given-names></name><name><surname>Olson</surname><given-names>L. D.</given-names></name><name><surname>Watson</surname><given-names>D. A.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Transcriptional profile of isoproterenol-induced cardiomyopathy and comparison to exercise-induced cardiac hypertrophy and human cardiac failure</article-title>. <source>BMC Physiol</source>. <volume>9</volume>:<fpage>23</fpage>
<pub-id pub-id-type="doi">10.1186/1472-6793-9-23</pub-id><?supplied-pmid 20003209?><pub-id pub-id-type="pmid">20003209</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gardner</surname><given-names>D. G.</given-names></name></person-group> (<year>2003</year>). <article-title>Natriuretic peptides: markers or modulators of cardiac hypertrophy?</article-title>
<source>Trends Endocrinol. Metab</source>. <volume>14</volume>, <fpage>411</fpage>&#8211;<lpage>416</lpage>
<pub-id pub-id-type="doi">10.1016/S1043-2760(03)00113-9</pub-id><?supplied-pmid 14580760?><pub-id pub-id-type="pmid">14580760</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geenen</surname><given-names>D.</given-names></name><name><surname>Buttrick</surname><given-names>P.</given-names></name><name><surname>Scheuer</surname><given-names>J.</given-names></name></person-group> (<year>1988</year>). <article-title>Cardiovascular and hormonal responses to swimming and running in the rat</article-title>. <source>J. Appl. Physiol. (1985)</source>
<volume>65</volume>, <fpage>116</fpage>&#8211;<lpage>123</lpage>
<?supplied-pmid 3403456?><pub-id pub-id-type="pmid">3403456</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heineke</surname><given-names>J.</given-names></name><name><surname>Molkentin</surname><given-names>J. D.</given-names></name></person-group> (<year>2006</year>). <article-title>Regulation of cardiac hypertrophy by intracellular signalling pathways</article-title>. <source>Nat. Rev. Mol. Cell Biol</source>. <volume>7</volume>, <fpage>589</fpage>&#8211;<lpage>600</lpage>
<pub-id pub-id-type="doi">10.1038/nrm1983</pub-id><?supplied-pmid 16936699?><pub-id pub-id-type="pmid">16936699</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henry</surname><given-names>G. D.</given-names></name><name><surname>Winstanley</surname><given-names>M. A.</given-names></name><name><surname>Dalgarno</surname><given-names>D. C.</given-names></name><name><surname>Scott</surname><given-names>G. M.</given-names></name><name><surname>Levine</surname><given-names>B. A.</given-names></name><name><surname>Trayer</surname><given-names>I. P.</given-names></name></person-group> (<year>1985</year>). <article-title>Characterization of the actin-binding site on the alkali light chain of myosin</article-title>. <source>Biochim. Biophys. Acta</source>
<volume>830</volume>, <fpage>233</fpage>&#8211;<lpage>243</lpage>
<pub-id pub-id-type="doi">10.1016/0167-4838(85)90279-1</pub-id><?supplied-pmid 4027251?><pub-id pub-id-type="pmid">4027251</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez</surname><given-names>O. M.</given-names></name><name><surname>Jones</surname><given-names>M.</given-names></name><name><surname>Guzman</surname><given-names>G.</given-names></name><name><surname>Szczesna-Cordary</surname><given-names>D.</given-names></name></person-group> (<year>2007</year>). <article-title>Myosin essential light chain in health and disease</article-title>. <source>Am. J. Physiol. Heart Circ. Physiol</source>. <volume>292</volume>, <fpage>H1643</fpage>&#8211;<lpage>H1654</lpage>
<pub-id pub-id-type="doi">10.1152/ajpheart.00931.2006</pub-id><?supplied-pmid 17142342?><pub-id pub-id-type="pmid">17142342</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hidalgo</surname><given-names>C.</given-names></name><name><surname>Saripalli</surname><given-names>C.</given-names></name><name><surname>Granzier</surname><given-names>H. L.</given-names></name></person-group> (<year>2014</year>). <article-title>Effect of exercise training on post-translational and post-transcriptional regulation of titin stiffness in striated muscle of wild type and IG KO mice</article-title>. <source>Arch. Biochem. Biophys</source>. <volume>552&#8211;553</volume>, <fpage>100</fpage>&#8211;<lpage>107</lpage>
<pub-id pub-id-type="doi">10.1016/j.abb.2014.02.010</pub-id><?supplied-pmid 24603287?><pub-id pub-id-type="pmid">24603287</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>T. L.</given-names></name><name><surname>Einsenberg</surname><given-names>E.</given-names></name><name><surname>Greene</surname><given-names>L. E.</given-names></name></person-group> (<year>1980</year>). <article-title>Theoretical model for the cooperative equilibrium binding of myosin subfragment-1 to the actin-troponin-tropomyosin complex</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A</source>. <volume>77</volume>, <fpage>3186</fpage>&#8211;<lpage>3190</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.77.6.3186</pub-id><?supplied-pmid 10627230?><pub-id pub-id-type="pmid">10627230</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>C. Y.</given-names></name></person-group> (<year>2010</year>). <article-title>Hypertrophic cardiomyopathy</article-title>. <source>Heart Fail. Clin</source>. <volume>6</volume>, <fpage>141</fpage>&#8211;<lpage>159</lpage>
<pub-id pub-id-type="doi">10.1016/j.hfc.2009.12.001</pub-id><pub-id pub-id-type="pmid">20347784</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>C. Y.</given-names></name><name><surname>Lopez</surname><given-names>B.</given-names></name><name><surname>Coelho-Filho</surname><given-names>O. R.</given-names></name><name><surname>Lakdawala</surname><given-names>N. K.</given-names></name><name><surname>Cirino</surname><given-names>A. L.</given-names></name><name><surname>Jarolim</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy</article-title>. <source>N. Engl. J. Med</source>. <volume>363</volume>, <fpage>552</fpage>&#8211;<lpage>563</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1002659</pub-id><?supplied-pmid 20818890?><pub-id pub-id-type="pmid">20818890</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoskins</surname><given-names>A. C.</given-names></name><name><surname>Jacques</surname><given-names>A.</given-names></name><name><surname>Bardswell</surname><given-names>S. C.</given-names></name><name><surname>McKenna</surname><given-names>W. J.</given-names></name><name><surname>Tsang</surname><given-names>V.</given-names></name><name><surname>Dos Remedios</surname><given-names>C. G.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Normal passive viscoelasticity but abnormal myofibrillar force generation in human hypertrophic cardiomyopathy</article-title>. <source>J. Mol. Cell. Cardiol</source>. <volume>49</volume>, <fpage>737</fpage>&#8211;<lpage>745</lpage>
<pub-id pub-id-type="doi">10.1016/j.yjmcc.2010.06.006</pub-id><?supplied-pmid 20615414?><pub-id pub-id-type="pmid">20615414</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>W.</given-names></name><name><surname>Liang</surname><given-names>J.</given-names></name><name><surname>Kazmierczak</surname><given-names>K.</given-names></name><name><surname>Muthu</surname><given-names>P.</given-names></name><name><surname>Duggal</surname><given-names>D.</given-names></name><name><surname>Farman</surname><given-names>G. P.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Hypertrophic cardiomyopathy associated lys104glu mutation in the myosin regulatory light chain causes diastolic disturbance in mice</article-title>. <source>J. Mol. Cell. Cardiol</source>. <volume>74</volume>, <fpage>318</fpage>&#8211;<lpage>329</lpage>
<pub-id pub-id-type="doi">10.1016/j.yjmcc.2014.06.011</pub-id><?supplied-pmid 24992035?><pub-id pub-id-type="pmid">24992035</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>J. J.</given-names></name><name><surname>Chien</surname><given-names>K. R.</given-names></name></person-group> (<year>1999</year>). <article-title>Signaling pathways for cardiac hypertrophy and failure</article-title>. <source>N. Engl. J. Med</source>. <volume>341</volume>, <fpage>1276</fpage>&#8211;<lpage>1283</lpage>
<pub-id pub-id-type="doi">10.1056/NEJM199910213411706</pub-id><?supplied-pmid 10528039?><pub-id pub-id-type="pmid">10528039</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iemitsu</surname><given-names>M.</given-names></name><name><surname>Miyauchi</surname><given-names>T.</given-names></name><name><surname>Maeda</surname><given-names>S.</given-names></name><name><surname>Sakai</surname><given-names>S.</given-names></name><name><surname>Kobayashi</surname><given-names>T.</given-names></name><name><surname>Fujii</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>Physiological and pathological cardiac hypertrophy induce different molecular phenotypes in the rat</article-title>. <source>Am. J. Physiol. Regul. Integr. Comp. Physiol</source>. <volume>281</volume>, <fpage>R2029</fpage>&#8211;<lpage>R2036</lpage>
<?supplied-pmid 11705790?><pub-id pub-id-type="pmid">11705790</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>R.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Lu</surname><given-names>H.</given-names></name><name><surname>Ryan</surname><given-names>A. M.</given-names></name><name><surname>Ogasawara</surname><given-names>A. K.</given-names></name><etal/></person-group> (<year>2000</year>). <article-title>Effects of exercise training on cardiac function, gene expression, and apoptosis in rats</article-title>. <source>Am. J. Physiol. Heart Circ. Physiol</source>. <volume>279</volume>, <fpage>H2994</fpage>&#8211;<lpage>H3002</lpage>
<?supplied-pmid 11087257?><pub-id pub-id-type="pmid">11087257</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kazmierczak</surname><given-names>K.</given-names></name><name><surname>Muthu</surname><given-names>P.</given-names></name><name><surname>Huang</surname><given-names>W.</given-names></name><name><surname>Jones</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Szczesna-Cordary</surname><given-names>D.</given-names></name></person-group> (<year>2012</year>). <article-title>Myosin regulatory light chain mutation found in hypertrophic cardiomyopathy patients increases isometric force production in transgenic mice</article-title>. <source>Biochem. J</source>. <volume>442</volume>, <fpage>95</fpage>&#8211;<lpage>103</lpage>
<pub-id pub-id-type="doi">10.1042/BJ20111145</pub-id><?supplied-pmid 22091967?><pub-id pub-id-type="pmid">22091967</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kazmierczak</surname><given-names>K.</given-names></name><name><surname>Paulino</surname><given-names>E. C.</given-names></name><name><surname>Huang</surname><given-names>W.</given-names></name><name><surname>Muthu</surname><given-names>P.</given-names></name><name><surname>Liang</surname><given-names>J.</given-names></name><name><surname>Yuan</surname><given-names>C. C.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Discrete effects of A57G-myosin essential light chain mutation associated with familial hypertrophic cardiomyopathy</article-title>. <source>Am. J. Physiol. Heart Circ. Physiol</source>. <volume>305</volume>, <fpage>H575</fpage>&#8211;<lpage>H589</lpage>
<pub-id pub-id-type="doi">10.1152/ajpheart.00107.2013</pub-id><?supplied-pmid 23748425?><pub-id pub-id-type="pmid">23748425</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kazmierczak</surname><given-names>K.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Jones</surname><given-names>M.</given-names></name><name><surname>Guzman</surname><given-names>G.</given-names></name><name><surname>Hernandez</surname><given-names>O. M.</given-names></name><name><surname>Kerrick</surname><given-names>W. G. L.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>The role of the N-terminus of the myosin essential light chain in cardiac muscle contraction</article-title>. <source>J. Mol. Biol</source>. <volume>387</volume>, <fpage>706</fpage>&#8211;<lpage>725</lpage>
<pub-id pub-id-type="doi">10.1016/j.jmb.2009.02.006</pub-id><?supplied-pmid 19361417?><pub-id pub-id-type="pmid">19361417</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>R. T.</given-names></name><name><surname>Bloch</surname><given-names>K. D.</given-names></name><name><surname>Pfeffer</surname><given-names>J. M.</given-names></name><name><surname>Pfeffer</surname><given-names>M. A.</given-names></name><name><surname>Neer</surname><given-names>E. J.</given-names></name><name><surname>Seidman</surname><given-names>C. E.</given-names></name></person-group> (<year>1988</year>). <article-title>Atrial natriuretic factor gene expression in ventricles of rats with spontaneous biventricular hypertrophy</article-title>. <source>J. Clin. Invest</source>. <volume>81</volume>, <fpage>431</fpage>&#8211;<lpage>434</lpage>
<pub-id pub-id-type="doi">10.1172/JCI113337</pub-id><?supplied-pmid 2963021?><pub-id pub-id-type="pmid">2963021</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S. C.</given-names></name><name><surname>Stevens</surname><given-names>T. L.</given-names></name><name><surname>Sandberg</surname><given-names>S. M.</given-names></name><name><surname>Heublein</surname><given-names>D. M.</given-names></name><name><surname>Nelson</surname><given-names>S. M.</given-names></name><name><surname>Jougasaki</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2002</year>). <article-title>The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure</article-title>. <source>J. Card. Fail</source>. <volume>8</volume>, <fpage>149</fpage>&#8211;<lpage>154</lpage>
<pub-id pub-id-type="doi">10.1054/jcaf.2002.125368</pub-id><?supplied-pmid 12140807?><pub-id pub-id-type="pmid">12140807</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>W.</given-names></name><name><surname>Hwang</surname><given-names>T. H.</given-names></name><name><surname>Kimura</surname><given-names>A.</given-names></name><name><surname>Park</surname><given-names>S. W.</given-names></name><name><surname>Satoh</surname><given-names>M.</given-names></name><name><surname>Nishi</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>Different expressivity of a ventricular essential myosin light chain gene Ala57Gly mutation in familial hypertrophic cardiomyopathy</article-title>. <source>Am. Heart J</source>. <volume>141</volume>, <fpage>184</fpage>&#8211;<lpage>189</lpage>
<pub-id pub-id-type="doi">10.1067/mhj.2001.112487</pub-id><?supplied-pmid 11174330?><pub-id pub-id-type="pmid">11174330</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>D.</given-names></name><name><surname>Garrison</surname><given-names>R. J.</given-names></name><name><surname>Savage</surname><given-names>D. D.</given-names></name><name><surname>Kannel</surname><given-names>W. B.</given-names></name><name><surname>Castelli</surname><given-names>W. P.</given-names></name></person-group> (<year>1990</year>). <article-title>Prognostic implications of echocardiographically determined left ventricular mass in the framingham heart study</article-title>. <source>N. Engl. J. Med</source>. <volume>322</volume>, <fpage>1561</fpage>&#8211;<lpage>1566</lpage>
<pub-id pub-id-type="doi">10.1056/NEJM199005313222203</pub-id><?supplied-pmid 2139921?><pub-id pub-id-type="pmid">2139921</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorell</surname><given-names>B. H.</given-names></name><name><surname>Carabello</surname><given-names>B. A.</given-names></name></person-group> (<year>2000</year>). <article-title>Left ventricular hypertrophy: pathogenesis, detection, and prognosis</article-title>. <source>Circulation</source>
<volume>102</volume>, <fpage>470</fpage>&#8211;<lpage>479</lpage>
<pub-id pub-id-type="doi">10.1161/01.CIR.102.4.470</pub-id><?supplied-pmid 10908222?><pub-id pub-id-type="pmid">10908222</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michael</surname><given-names>J. J.</given-names></name><name><surname>Gollapudi</surname><given-names>S. K.</given-names></name><name><surname>Ford</surname><given-names>S. J.</given-names></name><name><surname>Kazmierczak</surname><given-names>K.</given-names></name><name><surname>Szczesna-Cordary</surname><given-names>D.</given-names></name><name><surname>Chandra</surname><given-names>M.</given-names></name></person-group> (<year>2013</year>). <article-title>Deletion of 1-43 amino acids in cardiac myosin essential light chain blunts length dependency of Ca(2+) sensitivity and cross-bridge detachment kinetics</article-title>. <source>Am. J. Physiol. Heart Circ. Physiol</source>. <volume>304</volume>, <fpage>H253</fpage>&#8211;<lpage>H259</lpage>
<pub-id pub-id-type="doi">10.1152/ajpheart.00572.2012</pub-id><?supplied-pmid 23144314?><pub-id pub-id-type="pmid">23144314</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michels</surname><given-names>M.</given-names></name><name><surname>Soliman</surname><given-names>O. I.</given-names></name><name><surname>Phefferkorn</surname><given-names>J.</given-names></name><name><surname>Hoedemaekers</surname><given-names>Y. M.</given-names></name><name><surname>Kofflard</surname><given-names>M. J.</given-names></name><name><surname>Dooijes</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers</article-title>. <source>Eur. Heart J</source>. <volume>30</volume>, <fpage>2593</fpage>&#8211;<lpage>2598</lpage>
<pub-id pub-id-type="doi">10.1093/eurheartj/ehp306</pub-id><?supplied-pmid 19666645?><pub-id pub-id-type="pmid">19666645</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milligan</surname><given-names>R. A.</given-names></name><name><surname>Whittaker</surname><given-names>M.</given-names></name><name><surname>Safer</surname><given-names>D.</given-names></name></person-group> (<year>1990</year>). <article-title>Molecular structure of F-actin and location of surface binding sites</article-title>. <source>Nature</source>
<volume>348</volume>, <fpage>217</fpage>&#8211;<lpage>221</lpage>
<pub-id pub-id-type="doi">10.1038/348217a0</pub-id><?supplied-pmid 2234090?><pub-id pub-id-type="pmid">2234090</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morano</surname><given-names>I.</given-names></name></person-group> (<year>1999</year>). <article-title>Tuning the human heart molecular motors by myosin light chains</article-title>. <source>J. Mol. Med</source>. <volume>77</volume>, <fpage>544</fpage>&#8211;<lpage>555</lpage>
<pub-id pub-id-type="doi">10.1007/s001099900031</pub-id><?supplied-pmid 10494800?><pub-id pub-id-type="pmid">10494800</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morano</surname><given-names>I.</given-names></name><name><surname>Ritter</surname><given-names>O.</given-names></name><name><surname>Bonz</surname><given-names>A.</given-names></name><name><surname>Timek</surname><given-names>T.</given-names></name><name><surname>Vahl</surname><given-names>C. F.</given-names></name><name><surname>Michel</surname><given-names>G.</given-names></name></person-group> (<year>1995</year>). <article-title>Myosin light chain-actin interaction regulates cardiac contractility</article-title>. <source>Circ. Res</source>. <volume>76</volume>, <fpage>720</fpage>&#8211;<lpage>725</lpage>
<pub-id pub-id-type="doi">10.1161/01.RES.76.5.720</pub-id><?supplied-pmid 7728988?><pub-id pub-id-type="pmid">7728988</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muthu</surname><given-names>P.</given-names></name><name><surname>Kazmierczak</surname><given-names>K.</given-names></name><name><surname>Jones</surname><given-names>M.</given-names></name><name><surname>Szczesna-Cordary</surname><given-names>D.</given-names></name></person-group> (<year>2012</year>). <article-title>The effect of myosin RLC phosphorylation in normal and cardiomyopathic mouse hearts</article-title>. <source>J. Cell. Mol. Med</source>. <volume>16</volume>, <fpage>911</fpage>&#8211;<lpage>919</lpage>
<pub-id pub-id-type="doi">10.1111/j.1582-4934.2011.01371.x</pub-id><?supplied-pmid 21696541?><pub-id pub-id-type="pmid">21696541</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muthu</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Yuan</surname><given-names>C. C.</given-names></name><name><surname>Kazmierczak</surname><given-names>K.</given-names></name><name><surname>Huang</surname><given-names>W.</given-names></name><name><surname>Hernandez</surname><given-names>O. M.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Structural and functional aspects of the myosin essential light chain in cardiac muscle contraction</article-title>. <source>FASEB J</source>. <volume>25</volume>, <fpage>4394</fpage>&#8211;<lpage>4405</lpage>
<pub-id pub-id-type="doi">10.1096/fj.11-191973</pub-id><?supplied-pmid 21885653?><pub-id pub-id-type="pmid">21885653</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakagawa</surname><given-names>O.</given-names></name><name><surname>Ogawa</surname><given-names>Y.</given-names></name><name><surname>Itoh</surname><given-names>H.</given-names></name><name><surname>Suga</surname><given-names>S.</given-names></name><name><surname>Komatsu</surname><given-names>Y.</given-names></name><name><surname>Kishimoto</surname><given-names>I.</given-names></name><etal/></person-group> (<year>1995</year>). <article-title>Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an &#8220;emergency&#8221; cardiac hormone against ventricular overload</article-title>. <source>J. Clin. Invest</source>. <volume>96</volume>, <fpage>1280</fpage>&#8211;<lpage>1287</lpage>
<pub-id pub-id-type="doi">10.1172/JCI118162</pub-id><?supplied-pmid 7657802?><pub-id pub-id-type="pmid">7657802</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nixon</surname><given-names>B. R.</given-names></name><name><surname>Thawornkaiwong</surname><given-names>A.</given-names></name><name><surname>Jin</surname><given-names>J.</given-names></name><name><surname>Brundage</surname><given-names>E. A.</given-names></name><name><surname>Little</surname><given-names>S. C.</given-names></name><name><surname>Davis</surname><given-names>J. P.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>AMP-activated protein kinase phosphorylates cardiac troponin I at Ser-150 to increase myofilament calcium sensitivity and blunt PKA-dependent function</article-title>. <source>J. Biol. Chem</source>. <volume>287</volume>, <fpage>19136</fpage>&#8211;<lpage>19147</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M111.323048</pub-id><?supplied-pmid 22493448?><pub-id pub-id-type="pmid">22493448</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rayment</surname><given-names>I.</given-names></name><name><surname>Rypniewski</surname><given-names>W. R.</given-names></name><name><surname>Schmidt-Base</surname><given-names>K.</given-names></name><name><surname>Smith</surname><given-names>R.</given-names></name><name><surname>Tomchick</surname><given-names>D. R.</given-names></name><name><surname>Benning</surname><given-names>M. M.</given-names></name><etal/></person-group> (<year>1993</year>). <article-title>Three-dimensional structure of myosin subfragment-1: a molecular motor</article-title>. <source>Science</source>
<volume>261</volume>, <fpage>50</fpage>&#8211;<lpage>58</lpage>
<pub-id pub-id-type="doi">10.1126/science.8316857</pub-id><?supplied-pmid 8316857?><pub-id pub-id-type="pmid">8316857</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rockman</surname><given-names>H. A.</given-names></name><name><surname>Ono</surname><given-names>S.</given-names></name><name><surname>Ross</surname><given-names>R. S.</given-names></name><name><surname>Jones</surname><given-names>L. R.</given-names></name><name><surname>Karimi</surname><given-names>M.</given-names></name><name><surname>Bhargava</surname><given-names>V.</given-names></name><etal/></person-group> (<year>1994</year>). <article-title>Molecular and physiological alterations in murine ventricular dysfunction</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A</source>. <volume>91</volume>, <fpage>2694</fpage>&#8211;<lpage>2698</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.91.7.2694</pub-id><?supplied-pmid 8146176?><pub-id pub-id-type="pmid">8146176</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadayappan</surname><given-names>S.</given-names></name><name><surname>Gulick</surname><given-names>J.</given-names></name><name><surname>Klevitsky</surname><given-names>R.</given-names></name><name><surname>Lorenz</surname><given-names>J. N.</given-names></name><name><surname>Sargent</surname><given-names>M.</given-names></name><name><surname>Molkentin</surname><given-names>J. D.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Cardiac myosin binding protein-C phosphorylation in a {beta}-myosin heavy chain background</article-title>. <source>Circulation</source>
<volume>119</volume>, <fpage>1253</fpage>&#8211;<lpage>1262</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.108.798983</pub-id><?supplied-pmid 19237661?><pub-id pub-id-type="pmid">19237661</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawicki</surname><given-names>G.</given-names></name><name><surname>Leon</surname><given-names>H.</given-names></name><name><surname>Sawicka</surname><given-names>J.</given-names></name><name><surname>Sariahmetoglu</surname><given-names>M.</given-names></name><name><surname>Schulze</surname><given-names>C. J.</given-names></name><name><surname>Scott</surname><given-names>P. G.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2</article-title>. <source>Circulation</source>
<volume>112</volume>, <fpage>544</fpage>&#8211;<lpage>552</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.104.531616</pub-id><?supplied-pmid 16027249?><pub-id pub-id-type="pmid">16027249</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sequeira</surname><given-names>V.</given-names></name><name><surname>Wijnker</surname><given-names>P. J.</given-names></name><name><surname>Nijenkamp</surname><given-names>L. L.</given-names></name><name><surname>Kuster</surname><given-names>D. W.</given-names></name><name><surname>Najafi</surname><given-names>A.</given-names></name><name><surname>Witjas-Paalberends</surname><given-names>E. R.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations</article-title>. <source>Circ. Res</source>. <volume>112</volume>, <fpage>1491</fpage>&#8211;<lpage>1505</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.111.300436</pub-id><?supplied-pmid 23508784?><pub-id pub-id-type="pmid">23508784</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutoh</surname><given-names>K.</given-names></name></person-group> (<year>1982</year>). <article-title>An actin-binding site on the 20K fragment of myosin subfragment 1</article-title>. <source>Biochemistry</source>
<volume>21</volume>, <fpage>4800</fpage>&#8211;<lpage>4804</lpage>
<pub-id pub-id-type="doi">10.1021/bi00262a043</pub-id><?supplied-pmid 7138830?><pub-id pub-id-type="pmid">7138830</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sweeney</surname><given-names>H. L.</given-names></name><name><surname>Bowman</surname><given-names>B. F.</given-names></name><name><surname>Stull</surname><given-names>J. T.</given-names></name></person-group> (<year>1993</year>). <article-title>Myosin light chain phosphorylation in vertebrate striated muscle: regulation and function</article-title>. <source>Am. J. Physiol</source>. <volume>264</volume>, <fpage>C1085</fpage>&#8211;<lpage>C1095</lpage>
<?supplied-pmid 8388631?><pub-id pub-id-type="pmid">8388631</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Timson</surname><given-names>D. J.</given-names></name></person-group> (<year>2003</year>). <article-title>Fine tuning the myosin motor: the role of the essential light chain in striated muscle myosin</article-title>. <source>Biochimie</source>
<volume>85</volume>, <fpage>639</fpage>&#8211;<lpage>645</lpage>
<pub-id pub-id-type="doi">10.1016/S0300-9084(03)00131-7</pub-id><?supplied-pmid 14505818?><pub-id pub-id-type="pmid">14505818</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Timson</surname><given-names>D. J.</given-names></name><name><surname>Trayer</surname><given-names>H. R.</given-names></name><name><surname>Trayer</surname><given-names>I. P.</given-names></name></person-group> (<year>1998</year>). <article-title>The N-terminus of A1-type myosin essential light chains binds actin and modulates myosin motor function</article-title>. <source>Eur. J. Biochem</source>. <volume>255</volume>, <fpage>654</fpage>&#8211;<lpage>662</lpage>
<pub-id pub-id-type="doi">10.1046/j.1432-1327.1998.2550654.x</pub-id><?supplied-pmid 9738905?><pub-id pub-id-type="pmid">9738905</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trayer</surname><given-names>I. P.</given-names></name><name><surname>Trayer</surname><given-names>H. R.</given-names></name><name><surname>Levine</surname><given-names>B. A.</given-names></name></person-group> (<year>1987</year>). <article-title>Evidence that the N-terminal region of A1-light chain of myosin interacts directly with the C-terminal region of actin. A proton magnetic resonance study</article-title>. <source>Eur. J. Biochem</source>. <volume>164</volume>, <fpage>259</fpage>&#8211;<lpage>266</lpage>
<pub-id pub-id-type="doi">10.1111/j.1432-1033.1987.tb11019.x</pub-id><?supplied-pmid 3549306?><pub-id pub-id-type="pmid">3549306</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuruda</surname><given-names>T.</given-names></name><name><surname>Boerrigter</surname><given-names>G.</given-names></name><name><surname>Huntley</surname><given-names>B. K.</given-names></name><name><surname>Noser</surname><given-names>J. A.</given-names></name><name><surname>Cataliotti</surname><given-names>A.</given-names></name><name><surname>Costello-Boerrigter</surname><given-names>L. C.</given-names></name><etal/></person-group> (<year>2002</year>). <article-title>Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases</article-title>. <source>Circ. Res</source>. <volume>91</volume>, <fpage>1127</fpage>&#8211;<lpage>1134</lpage>
<pub-id pub-id-type="doi">10.1161/01.RES.0000046234.73401.70</pub-id><?supplied-pmid 12480813?><pub-id pub-id-type="pmid">12480813</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Dijk</surname><given-names>S. J.</given-names></name><name><surname>Dooijes</surname><given-names>D.</given-names></name><name><surname>Dos Remedios</surname><given-names>C.</given-names></name><name><surname>Michels</surname><given-names>M.</given-names></name><name><surname>Lamers</surname><given-names>J. M.</given-names></name><name><surname>Winegrad</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction</article-title>. <source>Circulation</source>
<volume>119</volume>, <fpage>1473</fpage>&#8211;<lpage>1483</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.108.838672</pub-id><?supplied-pmid 19273718?><pub-id pub-id-type="pmid">19273718</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vangheluwe</surname><given-names>P.</given-names></name><name><surname>Louch</surname><given-names>W. E.</given-names></name><name><surname>Ver Heyen</surname><given-names>M.</given-names></name><name><surname>Sipido</surname><given-names>K.</given-names></name><name><surname>Raeymaekers</surname><given-names>L.</given-names></name><name><surname>Wuytack</surname><given-names>F.</given-names></name></person-group> (<year>2003</year>). <article-title>Ca2+ transport ATPase isoforms SERCA2a and SERCA2b are targeted to the same sites in the murine heart</article-title>. <source>Cell Calcium</source>
<volume>34</volume>, <fpage>457</fpage>&#8211;<lpage>464</lpage>
<pub-id pub-id-type="doi">10.1016/S0143-4160(03)00126-X</pub-id><?supplied-pmid 14572804?><pub-id pub-id-type="pmid">14572804</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Muthu</surname><given-names>P.</given-names></name><name><surname>Szczesna-Cordary</surname><given-names>D.</given-names></name><name><surname>Kawai</surname><given-names>M.</given-names></name></person-group> (<year>2013a</year>). <article-title>Characterizations of myosin essential light chain's N-terminal truncation mutant Delta43 in transgenic mouse papillary muscles by using tension transients in response to sinusoidal length alterations</article-title>. <source>J. Muscle Res. Cell Motil</source>. <volume>34</volume>, <fpage>93</fpage>&#8211;<lpage>105</lpage>
<pub-id pub-id-type="doi">10.1007/s10974-013-9337-x</pub-id><?supplied-pmid 23397074?><pub-id pub-id-type="pmid">23397074</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Muthu</surname><given-names>P.</given-names></name><name><surname>Szczesna-Cordary</surname><given-names>D.</given-names></name><name><surname>Kawai</surname><given-names>M.</given-names></name></person-group> (<year>2013b</year>). <article-title>Diversity and similarity of motor function and cross-bridge kinetics in papillary muscles of transgenic mice carrying myosin regulatory light chain mutations D166V and R58Q</article-title>. <source>J. Mol. Cell. Cardiol</source>. <volume>62</volume>, <fpage>153</fpage>&#8211;<lpage>163</lpage>
<pub-id pub-id-type="doi">10.1016/j.yjmcc.2013.05.012</pub-id><?supplied-pmid 23727233?><pub-id pub-id-type="pmid">23727233</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weeks</surname><given-names>K. L.</given-names></name><name><surname>McMullen</surname><given-names>J. R.</given-names></name></person-group> (<year>2011</year>). <article-title>The athlete's heart vs. the failing heart: can signaling explain the two distinct outcomes?</article-title>
<source>Physiology (Bethesda)</source>
<volume>26</volume>, <fpage>97</fpage>&#8211;<lpage>105</lpage>
<pub-id pub-id-type="doi">10.1152/physiol.00043.2010</pub-id><?supplied-pmid 21487028?><pub-id pub-id-type="pmid">21487028</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winstanley</surname><given-names>M. A.</given-names></name><name><surname>Trayer</surname><given-names>H. R.</given-names></name><name><surname>Trayer</surname><given-names>I. P.</given-names></name></person-group> (<year>1977</year>). <article-title>Role of the myosin light chains in binding to actin</article-title>. <source>FEBS Lett</source>. <volume>77</volume>, <fpage>239</fpage>&#8211;<lpage>242</lpage>
<pub-id pub-id-type="doi">10.1016/0014-5793(77)80242-1</pub-id><?supplied-pmid 558919?><pub-id pub-id-type="pmid">558919</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witjas-Paalberends</surname><given-names>E. R.</given-names></name><name><surname>Piroddi</surname><given-names>N.</given-names></name><name><surname>Stam</surname><given-names>K.</given-names></name><name><surname>Van Dijk</surname><given-names>S. J.</given-names></name><name><surname>Oliviera</surname><given-names>V. S.</given-names></name><name><surname>Ferrara</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy</article-title>. <source>Cardiovasc. Res</source>. <volume>99</volume>, <fpage>432</fpage>&#8211;<lpage>441</lpage>
<pub-id pub-id-type="doi">10.1093/cvr/cvt119</pub-id><?supplied-pmid 23674513?><pub-id pub-id-type="pmid">23674513</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Peng</surname><given-names>J.</given-names></name><name><surname>Campbell</surname><given-names>K. B.</given-names></name><name><surname>Labeit</surname><given-names>S.</given-names></name><name><surname>Granzier</surname><given-names>H.</given-names></name></person-group> (<year>2007</year>). <article-title>Hypothyroidism leads to increased collagen-based stiffness and re-expression of large cardiac titin isoforms with high compliance</article-title>. <source>J. Mol. Cell. Cardiol</source>. <volume>42</volume>, <fpage>186</fpage>&#8211;<lpage>195</lpage>
<pub-id pub-id-type="doi">10.1016/j.yjmcc.2006.09.017</pub-id><?supplied-pmid 17069849?><pub-id pub-id-type="pmid">17069849</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshimura</surname><given-names>M.</given-names></name><name><surname>Mizuno</surname><given-names>Y.</given-names></name><name><surname>Nakayama</surname><given-names>M.</given-names></name><name><surname>Sakamoto</surname><given-names>T.</given-names></name><name><surname>Sugiyama</surname><given-names>S.</given-names></name><name><surname>Kawano</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2002</year>). <article-title>B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure</article-title>. <source>Am. J. Med</source>. <volume>112</volume>, <fpage>716</fpage>&#8211;<lpage>720</lpage>
<pub-id pub-id-type="doi">10.1016/S0002-9343(02)01121-X</pub-id><?supplied-pmid 12079712?><pub-id pub-id-type="pmid">12079712</pub-id></mixed-citation></ref></ref-list></back></article>